The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy presented December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Additional research being featured at the press conference includes studies that examine
Full Post: New approaches to prevent blood clots
Exciting research into blood clotting by British Heart Foundation (BHF) researchers working at the University of Bristol will take us a step closer to better heart attack prevention and treatment.
Blood clots can be both life-saving and life-threatening; life-saving when they stop bleeding, but life-threatening when they form in diseased arteries feeding the heart. Here they can cause a heart attack, and do so in 146,000 people in the UK every year.
Current anti-clotting medicines, such as aspirin, reduce the risk of heart attack but in some people they can also cause excessive and dangerous bleeding.
Professor Alastair Poole and his BHF-funded team at the University of Bristol have found in mice that removal of a particular protein - PKCá - from specialist cells in the blood, called platelets, prevents dangerous clot formation but does not cause excessive bleeding.
Professor Poole explains: “Platelets are small cells in the blood that sense when a blood vessel has been damaged. They rapidly become very adhesive and form a protective plaster over the site of damage.”
In heart disease, fatty plaques build up in the walls of the arteries feeding the heart. If one of these ruptures the platelets clump together at the site of damage and can block the vessel, which can cause a heart attack.
Alastair Poole continues: “We’ve discovered that a protein called PKCá is a major controller of platelet stickiness - if you remove PKCá the dangerous blood clots don’t form. Equally important, and surprising, is that we’ve also found that absence of PKCá doesn’t seem to impair the normal control of bleeding, unlike some current anti-clotting medicines.
“It’s too early to put anti- PKCá drugs on the market but we’re excited to have made a step in the right direction towards the development of a new family of potentially useful anti-clotting medicines for heart patients.”
Professor Jeremy Pearson, Associate Medical Director at the BHF, said: “We do have some effective clot-busting and clot-preventing medicines at present, but they can be rather blunt instruments with serious side-effects such as increased bleeding.
“Platelets are a major component of the clotting processes that cause heart attacks and strokes, and many scientists around the world are trying to decipher their inner workings, interactions, and controls toward the development of better, safer, drugs for heart patients.
“BHF supporters in Bristol have helped us to sponsor these excellent scientists to carry out vital research into platelets. These findings are another step forward in the fight against heart disease.”
The research is published in The Journal of Clinical Investigation.
Please contact Cherry Lewis for further information.
http://www.bristol.ac.uk
--------------------------------------------------------------------------------------------
Related Posts:
Investigators at Children’s Research Institute, BloodCenter of Wisconsin’s Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient’s own platelets. In the October 2008 edition of Blood, investigators describe how a gene-modified bone marrow transplant can
Full Post: A new method to control bleeding in hemophilia
Images that for the first time show bleeding inside the heart after people have suffered a heart attack have been captured by scientists, in a new study published today in the journal Radiology. The research shows that the amount of bleeding can indicate how damaged a person’s heart is after a heart attack. The researchers,
Full Post: New scan shows bleeding inside heart after heart attack
Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association’s Scientific Sessions 2008. “The
Full Post: Rivaroxaban shows promise in patients with acute coronary syndrome
The Red Cross in Queensland has issued an urgent call for blood donors to come forward as the collection of blood has been restricted in Dengue-affected areas. As the Dengue fever outbreaks in Cairns and Townsville claim more victims each day, Queensland blood stocks have become depleted - in Cairns and Townsville more than 150
Full Post: Dengue outbreaks blamed for depletion of donated blood supply
Do you regularly take aspirin or antiplatelet medications? Do you know whether or not these drugs should be stopped before dental procedures or surgeries? According to a study published in the May/June issue of General Dentistry, the clinical, peer-reviewed journal of the Academy of General Dentistry (AGD), stopping antiplatelet medications prior to a surgical procedure
Full Post: Disclosure of medication to dentist can save a patient’s life --------------------------------------------------------------------------------------------
